Cargando…

Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption

Bosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hypertension (PAH). The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent administration, hepatotoxicity and systemic hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanna, Lydia A., Basalious, Emad B., ELGazayerly, Omaima N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241195/ https://www.ncbi.nlm.nih.gov/pubmed/28156176 http://dx.doi.org/10.1080/10717544.2016.1239661

Ejemplares similares

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Self-nanoemulsifying System Optimization for Higher Terconazole Solubilization and Non-Irritant Ocular Administration
por: Yousry, Carol, et al.
Publicado: (2020)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers
por: Castellví, Ivan, et al.
Publicado: (2020)

Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012)

Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema-history
por: Pham, Isabelle, et al.
Publicado: (2012)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis
por: Köse, Duygu, et al.
Publicado: (2021)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension
por: Liao, Shutan, et al.
Publicado: (2019)

Apoptosis and Inflammation Associated Gene Expressions in Monocrotaline-Induced Pulmonary Hypertensive Rats after Bosentan Treatment
por: Hong, Young Mi, et al.
Publicado: (2014)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN)
por: Vijay Kumar, J.R., et al.
Publicado: (2021)

Studies on the Vitrified and Cryomilled Bosentan
por: Minecka, Aldona, et al.
Publicado: (2021)

On the Physiology of Absorption and of Respiration
por: Bernard, M. C.
Publicado: (1853)

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
por: Beghetti, Maurice, et al.
Publicado: (2009)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
por: Berger, Rolf M. F., et al.
Publicado: (2017)

Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols
por: Lee, Hyo-Jung, et al.
Publicado: (2016)

The effect of Bosentan on healing of colonic anastomosis
por: Cetinkaya, Ziya, et al.
Publicado: (2006)

Gene Expression of Endothelin-1 and Endothelin Receptor A on Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment
por: Lim, Kyoung Ah, et al.
Publicado: (2010)

Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
por: Schuuring, Mark J, et al.
Publicado: (2010)

Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study
por: Liao, Shutan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_00seolaoompng7uipcbmetuig0